Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

Schizophrenia Research

Volumn 116, Issue 2-3, 2010, Pages 107-117

  Hough, David ^a   Gopal, Srihari ^a   Vijapurkar, Ujjwala ^a   Lim, Pilar ^a   Morozova, Margarita ^b   Eerdekens, Mariëlle ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Atypical antipsychotic; Long acting therapy; Paliperidone palmitate; Relapse; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PALIPERIDONE PALMITATE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INSOMNIA; IRRITABILITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; SINUS TACHYCARDIA; TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 74449091850     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.10.026     Document Type: Article

References (25)

1. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition (1994), The American Psychiatric Association, Washington, D.C 287-290
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
3. Cooper S.J., Butler A., Tweed J., Welch C., and Raniwalla J. Zotepine in the prevention of recurrence: A randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 150 (2000) 237-243
4. Emsley R., Rabinowitz J., and Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 163 (2006) 743-745
5. In: Guy W. (Ed). AIMS. Abnormal Involuntary Movement Scale, in ECDEU National Institute of Mental Health. Rockville, Md (1976) 534-537
6. Hough D., Lindenmayer J.-P., Gopal S., Melkote R., Lim P., Herben V., Yuen E., and Eerdekens M. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 6 (2009) 1022-1031
7. Juckel G., Schaub D., Fuchs N., Naumann U., Uhl I., Witthaus H., Hargarter L., Bierhoff H.W., and Brune M. Validation of the personal and social performance (PSP) scale in a German sample of acutely ill patients with schizophrenia. Schizophr. Res. 104 1-3 (2008) 287-293
8. Kane J.M. Treatment strategies to prevent relapse and encourage remission. J. Clin. Psychiatry 68 Suppl 1 (2007) 427-430
9. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., and Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 160 6 (2003) 1125-1132
10. Kawata A.K., and Revicki D.A. Psychometric properties of the personal and social performance scale (PSP) among individuals with schizophrenia living in the community. Qual. Life Res. 17 10 (2008) 1247-1256
11. Keith S.J., Kane J.M., Turner M., Conley R.R., and Nasrallah H.A. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J. Clin. Psychiatry 65 1 (2004) 120-131
12. Kramer M., Simpson G., Maciulis V., Kushner S., Vijapurkar U., Lim P., and Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27 1 (2007) 6-14
13. Kramer, M., Litman, R., Hough, D., Lane, R., Lim, P., Liu, Y., Eerdekens, M., submitted for publication. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Intl. J. Neuropsychopharm. doi:10.1017/S1461145709990988.
14. Kucukalic A., Dzubur-Kulenovic A., and Mehmedika-Suljic E. Relapse prevention in schizophrenia-new therapeutic challenges. Psychiatr. Danub. 19 4 (2007) 362-366
15. Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., and Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry 62 (2007) 1363-1370
16. Nasrallah H.A., and Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J. Psychopharmacol. 20 Suppl 6 (2006) 57-61
17. Nasrallah H.A., Gopal S., Gassmann-Mayer C., Quiroz J.A., Lim P., Eerdekens M., Yuen E., Palumbo J., and Hough D. Efficacy and safety of three doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic in schizophrenia. Presented at American Psychiatric Association Annual Meeting, Washington DC, May 2008 (2008)
18. Nasrallah H., Morosini P., and Gagnon D.D. Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia. Psychiatry Res. 161 2 (2008) 213-224
19. Pandina, G., Lindenmayer, J.P., Lull, J., Lim, P., Gopal, S., Kusumakar, V., Yuen, E., Herben, V., Palumbo, J., submitted for publication. A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J. Clin. Psychopharmacol.
20. Patrick D.L., Burns T., Morosini P., Rothman M., Gagnon D.D., Wild D., and Adriaenssen I. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr. Med. Res. Opin. 25 2 (2009) 325-338
21. Peuskens J., Trivedi J.K., Brecher M., Svensson O., Miller F., and Meulien D. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophr. Res. 98 (2008) (Suppl.) 14-15
22. Samtani M., Gopal S., Sliwa J.K., Haskins J.T., Alphs L., Stuyckens K., and Vermeulen A. Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulation. New Clinical Drug Evaluation Unit Meeting, June 29-July 2, Hollywood, Florida (2009). http://208.81.106.111/Poster%20Abstract%20Book%20Final.pdf Accessed September 28, 2009, http://208.81.106.111/Poster%20Abstract%20Book%20Final.pdf
23. Samtani M., Sliwa J.K., Haskins J.T., Alphs L., Stuyckens K., Herben V., and Vermeulen A. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. J. Pharm. Pract. 22 (2009) 216-217
24. Samtani M.N., Vermeulen A., and Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 48 9 (2009) 585-600
25. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (1970) 11-19